Please assess the completion status of the following clinical trial:

Trial Title: Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven locally advanced adenocarcinoma of the prostate, defined as 1 of the following:~  * T3-4, N0 or NX, M0~ * T2, PSA greater than 40 µg/L~ * T2, PSA greater than 20 µg/L AND Gleason score at least 8~* Diagnosis made within the past 6 months~* Gleason score and PSA known~* Pelvic lymph nodes must be clinically negative~  * Lymph nodes no more than 1.5 cm in greatest diameter by CT scan or MRI of the pelvis~ * Negative needle aspirate required for any lymph node more than 1.5 cm~ * If a lymph node dissection was performed, it must be histologically negative~* No small cell or transitional cell carcinoma by biopsy~* No bony metastases by bone scan~PATIENT CHARACTERISTICS:~Age:~* Under 80~Performance status:~* ECOG 0-2~Life expectancy:~* At least 5 years excluding malignancy~Hematopoietic:~* Hemoglobin at least 10.0 g/dL~* WBC at least 2,000/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin less than 2 times upper limit of normal (ULN)~* SGOT and SGPT less than 2 times ULN~* Alkaline phosphatase less than 2 times ULN~* No history of chronic liver disease~Renal:~* Creatinine less than 2 times ULN~Other:~* No contraindication to wide-field pelvic irradiation (e.g., inflammatory bowel disease or severe bladder irritability)~* No other malignancy within the past 5 years except nonmelanoma skin cancer~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* Not specified~Endocrine therapy:~* Prior hormonal therapy within the past 12 weeks allowed provided the following conditions are met:~  * Negative bone scan before beginning any hormonal therapy~ * Extracapsular extension remains palpable on rectal re-exam~ * Baseline PSA known before beginning any hormonal therapy~* At least 4-6 weeks since prior 5-alpha-reductase inhibitor (e.g., finasteride) for benign prostatic hypertrophy~Radiotherapy:~* No prior pelvic irradiation~Surgery:~* No prior radical prostatectomy~* Prior transurethral resection of the prostate allowed~Other:~* No prior cytotoxic anticancer therapy~* No other prior treatment for prostate cancer~* No other concurrent anticancer therapy unless documented disease progression

- Gender: MALE
- Minimum Age: None
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Total Androgen Blockade (Type: ACTIVE_COMPARATOR): None
- Total Androgen Blockade Vs TA Blockade Plus Pelvic Irradiation (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).